Valuation: Cogent Biosciences, Inc.

Market Cap 6.64B 5.77B 5.39B 4.95B 9.33B 633B 9.49B 63.54B 24.89B 316B 24.95B 24.39B 1,041B P/E 2026 *
-17x
P/E 2027 * -47.6x
Enterprise Value 6.59B 5.72B 5.34B 4.91B 9.25B 628B 9.41B 63.02B 24.68B 313B 24.74B 24.19B 1,033B EV / Sales 2026 *
665x
EV / Sales 2027 * 18.9x
Free-Float
99.5%
Yield 2026 *
-
Yield 2027 * -
1 day+1.62%
1 week-3.91%
Current month-0.18%
1 month+0.44%
3 months+6.09%
6 months+4.24%
Current year+9.40%
1 week 37.4
Extreme 37.4
42.11
1 month 37.04
Extreme 37.04
42.11
Current year 30.87
Extreme 30.87
42.11
1 year 10.38
Extreme 10.38
43.73
3 years 3.67
Extreme 3.67
43.73
5 years 3.67
Extreme 3.67
43.73
10 years 3.67
Extreme 3.67
43.73
Manager TitleAgeSince
Chief Executive Officer 50 23/10/2020
Director of Finance/CFO 45 01/06/2018
Chief Tech/Sci/R&D Officer 52 06/04/2021
Director TitleAgeSince
Director/Board Member 68 01/02/2018
Director/Board Member 74 26/07/2019
Director/Board Member 59 26/07/2019
Date Insider Type Main position Quantity % Market Cap.
01/07/26 Free

Director

627 0.0004%
09/06/26 Free

Director

17,901 0.0105%
09/06/26 Free

Director

17,901 0.0105%
Change 5-day change 1-year change 3-year change Capi.($)
+1.45%-3.91%+240.88%+221.16% 6.64B
+0.05%+3.08%+38.17%+66.77% 56.7B
+0.33%-6.14%+23.32%+61.89% 51.97B
-1.43%+1.27%-14.06%-13.50% 23.33B
-0.38%-6.00%-9.42%+344.47% 21.34B
+1.65%-0.81%+33.84%-25.23% 17.44B
+9.91%-2.51%+188.84%+326.19% 14.77B
-0.25%-1.34%+47.77%+165.22% 13.84B
+1.90%+0.56%+439.92%+166.12% 12.12B
+1.42%-12.56%+59.51%+149.39% 11.14B
Average +1.59%-2.49%+104.88%+146.25% 22.93B
Weighted average by Cap. +0.96%-2.00%+63.16%+112.74%

Financials

2026 *2027 *
Net sales 9.9M 8.61M 8.04M 7.38M 13.91M 944M 14.15M 94.75M 37.11M 471M 37.2M 36.37M 1.55B 349M 303M 283M 260M 490M 33.25B 499M 3.34B 1.31B 16.58B 1.31B 1.28B 54.7B
Net income -392M -340M -318M -292M -550M -37.32B -560M -3.75B -1.47B -18.61B -1.47B -1.44B -61.39B -132M -114M -107M -98.09M -185M -12.55B -188M -1.26B -493M -6.26B -495M -484M -20.65B
Net Debt -55.22M -47.99M -44.8M -41.13M -77.56M -5.26B -78.91M -528M -207M -2.62B -207M -203M -8.66B -63.88M -55.51M -51.83M -47.58M -89.71M -6.09B -91.28M -611M -239M -3.04B -240M -235M -10.01B
Logo Cogent Biosciences, Inc.
Cogent Biosciences, Inc. is a clinical-stage biotechnology company. It is focused on developing precision therapies for genetically defined diseases. Its approach is to design rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its advanced program is bezuclastinib, also known as CGT9486, a highly selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis (SM), a serious and rare disease caused by unchecked proliferation of mast cells. The Company has on-going Phase I studies of its CNS-penetrant, selective mutant ErbB2 inhibitor and its potential best-in-class, wild-type-sparing, PI3Ka inhibitor. In addition, the Company’s research team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in KRAS and JAK2.
Employees
258
Date Price Change Volume
04/08/26 $38.86 -0.18% 1,406,506
31/07/26 $38.93 -5.88% 1,547,338
30/07/26 $41.36 +4.52% 1,835,760
29/07/26 $39.57 -2.70% 1,220,992
28/07/26 $40.67 +0.57% 1,133,724
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
38.86USD
Average target price
54.25USD
Spread / Average Target
+39.60%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. COGT Stock